Abu Dhabi, UAE — March 2026 — CellSave Arabia, the region’s first and largest private stem cell laboratory and a leader in regenerative medicine, part of CSG.BIO, has been qualified by Gilead and Kite to provide cell storage services for cell therapy treatment centers in the UAE. Through this collaboration, CellSave Arabia will serve as a qualified provider of cell storage services for cells used in Gilead and Kite’s treatment pathways for lymphoma patients.
Kite, a Gilead company, is the global leader in cell therapy, with a goal to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Today, over 32,000 patients worldwide have been treated with Kite’s CAR T-cell therapies, including YESCARTA® and TECARTUS®, and currently offers two approved CAR T-cell therapies across four indications in the UAE. CellSave Arabia, accredited by AABB, FDA, and ISO 2038, will ensure secure, high-standard storage and handling of cellular material, a critical step in CAR T-cell treatment delivery.
Alia Abdel-Razeq, COO of CellSave Arabia, said:
“Our mission has always been to place patients at the center of every innovation we pursue. Working alongside Gilead and Kite allows us to support lymphoma patients with the highest level of precision, safety, and care—ensuring their cells are preserved in the highest standards.”
Also read: UAE Marks International Day of Happiness with Focus on Wellbeing and Quality of Life
Eslam Khedr, Head of Oncology Regional Headquarters, Gilead and Kite Middle East added:
“CAR-T therapy is a truly individualised treatment with an intent to cure patients with difficult-to treat-blood cancers. At the heart of meeting the needs of these patients, their families, caregivers and their HCPs is ensuring the highest quality in the treatment delivery infrastructure. Kite has taken a unique approach to scaling the technology of cell therapy, combining capacity, speed, and reliability with the largest in-house cell therapy manufacturing network in the world to rapidly deliver products to our authorised treatment centers.”
The partnership underscores both organizations’ commitment to improving lymphoma treatment in the region and strengthens the UAE’s role as a regional hub for next-generation therapeutics and biomedical innovation.
